Noman Ali, MD
Department of Hospital Medicine, Division of Internal Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Hospital Medicine, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Hospital Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2016 | Baylor College of Medicine, Houston, Texas, US, MD |
| 2011 | Houston Baptist University, Houston, Texas, US, Chemistry, Molecular Biology, & Biochemistry, BS |
Postgraduate Training
| 2016-2019 | Clinical Residency, Internal Medicine, Baylor College of Medicine, Houston, Texas |
Licenses & Certifications
| 2022 | Medical License |
| 2019 | American Board of Internal Medicine |
| 2019 | DEA |
Experience & Service
Faculty Academic Appointments
Instructor, Department of Hospital Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2022
Administrative Appointments/Responsibilities
Medical Director, Department of Nocturnal Hospital Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - 2022
Medical Director, LabCorp, Houston, TX, 2021 - Present
Other Professional Positions
Emergency Planning Officer, University of Texas at MD Anderson Cancer Center, Houston, TX, 2020 - Present
Quality Officer, University of Texas at MD Anderson Cancer Center, Houston, TX, 2020 - 2020
Honors & Awards
| 2015 | Golden Humanism Honor Society |
| 2014 | Baylor College of Medicine Power of Professionalism Award, Baylor College of Medicine |
| 2012 | Baylor College of Medicine Humanism Award, Baylor College of Medicine |
| 2011 | Overall Best Chemistry Student Award |
| 2011 | Winner of 2011 HBU Research Symposium, Houston Baptist University |
| 2010 - 2011 | Recipient of the Sigma Pi Sigma Research Grant |
| 2010 - 2011 | Recipient of the Welch Scholar Research Grant |
| 2008 - 2011 | Dean's List, Houston Baptist University |
| 2008 - 2011 | Fondren Scholarship for Merit |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2023. Cancer Cachexia. Conference. The University of Texas MD Anderson Cancer Center, General Internal Medicine. Houston, TX, US.
- 2021. Implementing a Post Discharge Transition of Care Program for Cancer Patients Hospitalized with COVID-19. Conference. The University of Texas at MD Anderson Cancer Center. Houston, TX, US.
- 2021. Analysis of Extended Length of stay in Comprehensive Cancer Center. Conference. The University of Texas at MD Anderson Cancer Center. Houston, TX, US.
- 2020. Delirium in Cancer Patient. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2020. Restraint. Conference. The University of Texas at MD Anderson Cancer Center. Houston, TX, US.
- 2020. LOS Data. Conference. The University of Texas at MD Anderson Cancer Center. Houston, TX, US.
Selected Publications
Peer-Reviewed Articles
- Ali, N. Association of presenting symptoms with COVID-19 disease severity and outcomes among hospitalized patients with cancer and COVID-19. Journal of Clinical Oncology, 41(16_suppl)(41(16_suppl)), 2023. e-Pub 2023.
- Wang Y, Abu-Sbeih H, Mao E, Ali N, Ali FS, Qiao W, Lum P, Raju G, Shuttlesworth G, Stroehlein J, Diab A. “Immune-Checkpoint Inhibitor-Induced Diarrhea and Colitis in Patients with Advanced Malignancies: Retrospective Review at MD Anderson.”. Journal for ImmunoTherapy of Cancer 6(1), 2018. e-Pub 2018.
- Wang Y, MD, PhD, Abu-Sbeih H, MD, Mao E, MD, Ali N, MD, Qiao W, PhD, Trinh VA, PharmD, Zobniw C, PharmD, Johnson DH, MD, Samdani R, MD, Lum P, BBA, Shuttlesworth G, PhD, Blechacz B, MD, Bresalier R, MD, Miller E, MD, Thirumurthi S, MD, Richards D, MD, Raju G, MD, Stroehlein J, MD, Diab A, MD. Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis. Inflammatory Bowel Diseases, 2018. e-Pub 2018.
- Wang Y, Diab A, Ali N, Abu-Sbeih H, Johnson D, Lum P, Ma J, Shuttlesworth G, Trinh VA, Zobniw C. P103 ROLE OF INFLIXIMAB IN THE MANAGEMENT OF IMMUNE-CHECKPOINT INHIBITORS-MEDIATED COLITIS (ICI-C). Gastroenterology 154(1), 2018. e-Pub 2018.
Other Articles
- Ali, Noman, Joanna M Symptom Burden on Presentation as Determinants of Covid Severity, 2022.
- Ali, Noman, Tacara S Implementation of 3D CAM assessment as part of Delirium Algorithm, 2022.
- Ali, Noman In Analysis of Extended Length of Stay in a Comprehensive Cancer Center, 2021.
- Ali, Noman, Joanna M In Implementing a Post Discharge Transition of Care program of Cancer Patients Hospitalized with COVID-19 at Comprehensive Cancer Center, 2021.
- Ali N External Validation of the Mayo Delirium Prediction Tool in Individuals With Cancer. Mayo Clinic Proceeding.
Patient Reviews
CV information above last modified March 26, 2026